What's Hot

View all perspectives
      RT @synovialjoints: All for one or one for all? Lumper or splitter? Highlight from #ACR21 was session 6S403 looking at a

      Dr. Antoni Chan synovialjoints

      3 years 1 month ago
      All for one or one for all? Lumper or splitter? Highlight from #ACR21 was session 6S403 looking at axial involvement in AxSpa vs PsA. I share my thoughts here at https://t.co/i2nDvMklee @RheumNow https://t.co/62tRRiAcUJ
      RT @Janetbirdope: Serious infections beyond herpes zoster in both doses of #tofacitinib v #TNFi in Oral Surveillance. No

      Janet Pope Janetbirdope

      3 years 1 month ago
      Serious infections beyond herpes zoster in both doses of #tofacitinib v #TNFi in Oral Surveillance. Note this outcome was not powered to be stat sig. it is a comparison of SIE events #ACR21 abst#1684 @RheumNow https://t.co/uqME6ABXuC
      SLE Panel: Learning about Lupus

      Drs. Kathryn Dao, Janet Pope, Yuz Yusof, Bella Mehta and Pedro Castillo discuss lupus-

      Dr. John Cush RheumNow

      3 years 1 month ago
      SLE Panel: Learning about Lupus Drs. Kathryn Dao, Janet Pope, Yuz Yusof, Bella Mehta and Pedro Castillo discuss lupus-related data presented at #ACR21. @KDAO2011 @Janetbirdope @Yuz6Yusof @bella_mehta @_Castillo_Pedro https://t.co/RPl6ZqWS05 https://t.co/mdTyocBbr2
      RT @bonnialiu: Gout being sneaky🧐
      Common consult question is "infection or flare?" in patients with gout.

      @ACR21 ABS

      Bonnia Liu bonnialiu

      3 years 1 month ago
      Gout being sneaky🧐 Common consult question is "infection or flare?" in patients with gout. @ACR21 ABS0467 w/ Dr Michael Toprover: 🔸Calibrating DECT for LS-spine in gout patients. 🔹DECT signal = MSU deposition? 🔸Future data on back pain/gout flare/MSU🤞? @RheumaRepublic https://t.co/aDCusqBk8G
      RT @_Castillo_Pedro: Dr. Atul Deodhar with an excellent presentation on treatment in axSpA and axPsA. Note ustekinumab a

      Pedro Castillo _Castillo_Pedro

      3 years 1 month ago
      Dr. Atul Deodhar with an excellent presentation on treatment in axSpA and axPsA. Note ustekinumab and risankizumab did not show improvement in axSpA. However, these studies did not include axPsA. @ACR21 6S403 @RheumNow https://t.co/F73lvpF2at
      RT @SituationRheum: More thoughts from @ashira_md's talk on Gaslighting/microaggressions from #ACR21 ...

      (Q 1/2)
      Provid

      Elizabeth Graef SituationRheum

      3 years 1 month ago
      More thoughts from @ashira_md's talk on Gaslighting/microaggressions from #ACR21 ... (Q 1/2) Providers: have you ever been told you are difficult and/or challenging?
      RT @AkhilSoodMD: Abst 1661
      Scheir & colleagues identified patterns of multimorbidity and association w/ disability i

      Akhil Sood MD AkhilSoodMD

      3 years 1 month ago
      Abst 1661 Scheir & colleagues identified patterns of multimorbidity and association w/ disability in patients w/ early RA - In women: Depression significantly associated w/ disability - In men: HTN & Lung Disease significantly associated w/ disability #ACR21 @RheumNow https://t.co/0qkn1TcvOi
      RT @Janetbirdope: OK is this a swan or a swan song? Graph looks like a swan 🦢 but message is NO #MACE differences in

      Janet Pope Janetbirdope

      3 years 1 month ago
      OK is this a swan or a swan song? Graph looks like a swan 🦢 but message is NO #MACE differences in PsA on csDMARDs v #biologics #ACR21 abst#1833 @RheumNow https://t.co/TM91z5wiFY
      RT @Yuz6Yusof: #ACR21 #AbstrL21 Phase III RCT which stratified pts using FFS showed no superiority of Rituximab vs SOC f

      Md Yuzaiful Md Yusof Yuz6Yusof

      3 years 1 month ago
      #ACR21 #AbstrL21 Phase III RCT which stratified pts using FFS showed no superiority of Rituximab vs SOC for remission induction of EGPA #vasculitis at Day 180 (63.5% vs 60.4%). No difference in secondary endpoints, safety or subgroup analyses @RheumNow https://t.co/AbdAvlU0Bg https://t.co/yta1CM7hrs
      RT @Janetbirdope: So are we in an era of #monotherapy with bDMARDs in #PsA? Ustekinumab & Secukinumab not different

      Janet Pope Janetbirdope

      3 years 1 month ago
      So are we in an era of #monotherapy with bDMARDs in #PsA? Ustekinumab & Secukinumab not different w or without #MTX. Abst#L12 @RheumNow #ACR21 https://t.co/Zp5owTpLvm
      RT @Janetbirdope: Cycling bDMARDs in #PsA. Law of diminishing returns. The more you fail, the more you cycle BUT can we

      Janet Pope Janetbirdope

      3 years 1 month ago
      Cycling bDMARDs in #PsA. Law of diminishing returns. The more you fail, the more you cycle BUT can we break cycle by ⬆️adherence & health literacy, d/c smoking, use drug levels, biomarkers. Oh that in in future #ACR meetings! #ACR21 abst#1830 @RheumNow https://t.co/GyhgUGHWe8
      RT @uptoTate: Canadian study found no significant differences in effectiveness or tx survival among different TNFi, or i

      Dr. Rachel Tate uptoTate

      3 years 1 month ago
      Canadian study found no significant differences in effectiveness or tx survival among different TNFi, or in nr-axSpA or AS. Failure of 1st TNFi didn't diminish effectiveness or drug survival of additional TNFi. Abs 0938 #ACR21 #RheumNow @RheumNow https://t.co/u1efnfv2zA https://t.co/qsJw3nA9qn
      RT @kpoho: Handy overview of Jak/STAT pathways in rheumatic diseases and available inhibitors (Dr. Joost Swart). Happeni

      Katie Poholek kpoho

      3 years 1 month ago
      Handy overview of Jak/STAT pathways in rheumatic diseases and available inhibitors (Dr. Joost Swart). Happening now in the Pediatrics Hub (New Therapies & Biologic Safety in Pediatric Rheumatology​). #ACR21 #pedsrheum https://t.co/i4bYr4GKOP
      RT @Tuhina_Neogi: Similar effects in those with CKD stage 3, with also high proportion of achieving serum urate target &

      Tuhina Neogi, MD, PhD Tuhina_Neogi

      3 years 1 month ago
      Similar effects in those with CKD stage 3, with also high proportion of achieving serum urate target <6mg/dL (overall 99% of study sample achieved target during trial) https://t.co/gKvDJKoWuw
      RT @Tuhina_Neogi: Important #gout study (I'm biased): allopurinol is non-inferior to febuxostat with regards to gout fla

      Tuhina Neogi, MD, PhD Tuhina_Neogi

      3 years 1 month ago
      Important #gout study (I'm biased): allopurinol is non-inferior to febuxostat with regards to gout flare when used in a T2T approach, with no differences in AEs, including CV risk. 99% achieved serum urate target over course of trial. Key slides following. #ACR21 https://t.co/tWeGvZ4rKY

      Podcasts

      • Bah Humbug Vitamin D (12.20.2024)
      • 54K Peptic Ulcers Annually (12.13.2024)
      • Don’t Buy Guitars (12.6.2024)

      Catch up on Conference Podcasts

      Featured Video

      Do you get our email newsletter?

      Looking for the latest rheumatology news & trends? Sign up for the RheumNow weekday newsletter:

      This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

      Rheumnow.com is a news source dedicated to the field of Rheumatology. It is written by experts in the field, and written for rheumatologists and individuals working in related fields. Rheumnow.com provides daily updates on the site and in your inbox when you are signed up for our newsletter.

      Copyright 2024 All Rights Reserved.

      ×